{"filing":{"accession_number":"0001420720-26-000032","cik":"0001420720","ticker":"IBIO","company_name":"iBio, Inc.","form":"8-K","filing_date":"2026-10-19","report_date":"2026-10-14","primary_document":"ibio-20261014x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072026000032/ibio-20261014x8k.htm"},"events":[{"id":36087,"run_id":33272,"accession_number":"0001420720-26-000032","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"iBio held its Annual Meeting of Stockholders and disclosed results of six proposals voted on by shareholders, including election of Class III directors (William Clark and Gary Sender), ratification of Grassi \u0026 Co. as auditor, say-on-pay approval, authorization to increase authorized Common Stock from 275 million to 500 million shares, approval of Amendment No. 1 to the 2023 Omnibus Incentive Plan, and meeting adjournment.","company_name":"iBio, Inc.","ticker":"IBIO","filing_date":"2026-10-19","form":"8-K","submitted_at":null,"items":[{"id":40369,"accession_number":"0001420720-26-000032","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure reports stockholder approval of Amendment No. 1 to the iBio, Inc. 2023 Omnibus Incentive Plan, which modifies the evergreen provision governing the automatic annual increase in shares reserved for issuance under the equity compensation plan. This is a compensatory arrangement amendment affecting the pool of equity available for director and officer grants, falling squarely within Item 5.02(e) and the exec_compensation category. The amendment is material because it expands the equity reserve available for future compensation grants over a multi-year period (2027–2033).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T20:17:52.264874+00:00","company_name":"","ticker":null,"filing_date":""},{"id":40370,"accession_number":"0001420720-26-000032","item_number":"5.03","item_title":"Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"This disclosure reports a stockholder-approved amendment to iBio's Certificate of Incorporation increasing authorized Common Stock from 275 million to 500 million shares, filed with Delaware on October 16, 2026. While a routine governance matter, the substantial increase in authorized shares (81% expansion) is material to investors as it expands the company's capacity for future dilutive issuances and affects shareholder voting power, making it a governance event that does not fit a more specific category.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T20:17:52.264874+00:00","company_name":"","ticker":null,"filing_date":""},{"id":40371,"accession_number":"0001420720-26-000032","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure reports the results of six proposals voted on at iBio's Annual Meeting of Stockholders, including director elections (William Clark and Gary Sender as Class III directors), auditor ratification (Grassi \u0026 Co.), say-on-pay approval, authorization to increase common shares from 275M to 500M, approval of a plan amendment, and meeting adjournment. The filing explicitly states the vote tallies for each proposal, which is the core content of Item 5.07 shareholder vote results disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T20:17:52.264874+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40369,"accession_number":"0001420720-26-000032","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure reports stockholder approval of Amendment No. 1 to the iBio, Inc. 2023 Omnibus Incentive Plan, which modifies the evergreen provision governing the automatic annual increase in shares reserved for issuance under the equity compensation plan. This is a compensatory arrangement amendment affecting the pool of equity available for director and officer grants, falling squarely within Item 5.02(e) and the exec_compensation category. The amendment is material because it expands the equity reserve available for future compensation grants over a multi-year period (2027–2033).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T20:17:52.264874+00:00","company_name":"iBio, Inc.","ticker":"IBIO","filing_date":"2026-10-19"},{"id":40370,"accession_number":"0001420720-26-000032","item_number":"5.03","item_title":"Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"This disclosure reports a stockholder-approved amendment to iBio's Certificate of Incorporation increasing authorized Common Stock from 275 million to 500 million shares, filed with Delaware on October 16, 2026. While a routine governance matter, the substantial increase in authorized shares (81% expansion) is material to investors as it expands the company's capacity for future dilutive issuances and affects shareholder voting power, making it a governance event that does not fit a more specific category.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T20:17:52.264874+00:00","company_name":"iBio, Inc.","ticker":"IBIO","filing_date":"2026-10-19"},{"id":40371,"accession_number":"0001420720-26-000032","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure reports the results of six proposals voted on at iBio's Annual Meeting of Stockholders, including director elections (William Clark and Gary Sender as Class III directors), auditor ratification (Grassi \u0026 Co.), say-on-pay approval, authorization to increase common shares from 275M to 500M, approval of a plan amendment, and meeting adjournment. The filing explicitly states the vote tallies for each proposal, which is the core content of Item 5.07 shareholder vote results disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T20:17:52.264874+00:00","company_name":"iBio, Inc.","ticker":"IBIO","filing_date":"2026-10-19"}]}